Are Compounded Nasal Sprays Real Medicine? Yes — and Here's the Regulation

TL;DR

Yes, compounded nasal sprays dispensed by state-licensed pharmacies under FDCA Section 503A are legitimate medicine. Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections Expert The “real medicine” question conflates two different regulatory pathways — and the FDA explicitly recognizes both.

The honest answer

There is a persistent online narrative that anything compounded is “fake” or “not FDA-approved.” This is wrong, but it gets to a real distinction worth understanding.

There are two regulatory pathways relevant here:

1. The new-drug pathway (Section 505 of the FDCA). This is what gives you a drug like Dymista — a fixed-dose combination of azelastine and fluticasone propionate that went through clinical trials, NDA submission, and FDA approval as a single product. In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis Expert
2. The compounding pathway (Sections 503A and 503B of the FDCA). A licensed pharmacist (503A) or outsourcing facility (503B) combines FDA-approved drug substances into a personalized formulation in response to a valid prescription. The combination itself is not an NDA-approved product, but the underlying actives are FDA-approved, and the compounding is explicitly authorized by federal statute and regulated by state pharmacy boards plus the FDA.

Both are real medicine. They sit on different rails. A patient who has tried single-active OTC sprays without success and would benefit from a custom multi-active formulation is exactly who the compounding pathway exists to serve.

What compounding does NOT do: it does not generate new clinical trial data for the specific combination. The evidence base for “azelastine + fluticasone + oxymetazoline” has to be inferred from the evidence base for the individual actives plus published combination studies (Dymista’s RCTs, Meltzer/Berkowitz 2011 fluticasone furoate + oxymetazoline). That’s a real epistemic limitation patients should weigh — but it’s not the same as “fake medicine.”

What the evidence says

The regulatory framework is laid out plainly in FDA’s compounding Q&A.

The clinical case for combination therapy in allergic rhinitis is well-established, regardless of regulatory pathway. In a meta-analysis of three randomized Phase III trials (n=3,398 patients with moderate-to-severe seasonal allergic rhinitis), a single combined intranasal azelastine + fluticasone propionate spray reduced nasal symptoms more than either component alone or placebo, with improvement seen on the first day of treatment Expert Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398) 4 Expert

What the FDA explicitly says about Section 503A: it “applies to human drug compounding by a licensed pharmacist within a state-licensed pharmacy or federal facility, or by a licensed physician, that is not registered with FDA as an outsourcing facility under section 503B.” [3] The compounded product, when produced under a valid prescription with FDA-approved active ingredients meeting USP standards, is exempt from the new-drug approval requirement of §505. That exemption is the entire point of the statute.

What 503A pharmacies cannot do: they cannot mass-produce. They cannot make “essentially copies” of an FDA-approved drug (so they cannot make a generic Dymista knockoff for cost reasons). They cannot use bulk substances that aren’t on the FDA’s 503A list or covered by a USP/NF monograph. These limits exist for safety reasons and are actively enforced.

The clinical literature on multi-active nasal therapy: Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion 7 Guideline For nasal symptoms of allergic rhinitis, intranasal antihistamines such as azelastine act locally on the nasal lining and have a rapid onset; clinical trials show benefit comparable to oral second-generation antihistamines, with particular advantage in patients not adequately controlled on oral therapy Expert

Where Allermi fits

Allermi is the most-discussed example of a compounded telehealth nasal spray. Disclosure: BestAllergyNasalSprays editorially recommends Allermi where eligibility and evidence support it; we cite the same primary literature the company does. Allermi is designed for sustained daily use, with a prescribing allergist reviewing your response and adjusting your formula as needed Expert

The model is explicitly Section 503A: a board-certified allergist evaluates each patient via telehealth, writes a patient-specific prescription, and a state-licensed compounding pharmacy fills it. The combinations are personalized — a typical formula contains a corticosteroid (triamcinolone), a nasal antihistamine (azelastine), an anticholinergic (ipratropium), and optionally a micro-dosed alpha-agonist (oxymetazoline). Each is on-label for rhinitis. See Allermi’s regulatory and approach pages. Eligibility: 13+ in 39 US states (18+ in AK/NM/OR/SC; not in AR/DE/KS/MS/WV/ND/RI/DC); not prescribed in pregnancy or breastfeeding. Check eligibility. For comparison, see Allermi vs Dymista — the FDA-approved-vs-compounded head-to-head.

Summary & recommendations

Publish history

This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.